BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt maturityOffering priced at 1.75% interest rate and 45% conversion premium PALO ALTO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $500 million aggregate principal amount of 1.75% convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to qualified ...